Latest news

Two new members added to the glycerol-free product family

ArcticZymes presents Glycerol-free dsDNase and Glycerol-free HL-dsDNase, two new members of the glycerol-free family of products. The dsDNases are well known products used for specific removal of dsDNA from a range of solutions, including commercial qPCR mastermixes and RNA solutions. The convenient, glycerol-free format makes these enzymes suitable for automatization and lyophilization.

View the product brochure.

Glycerol-free dsDNase and Glycerol-free HL-dsDNase available for purchase now.

First Polymerase launched

ArcticZymes presents IsoPol™ DNA Polymerase, the first in a family of polymerases established to serve the genomic market segment. IsoPol™ DNA Polymerase is a low temperature polymerase, as opposed to PCR-related polymerases which are active at around 70ºC. Low temperature polymerases will enable novel technology development, serving markets that open up due to the increasing amount of available genetic information. The market for low temperature polymerases have been underserved, and ArcticZymes plans to provide a variety of low temperature polymerases to enable technology development for Gene Sequencing, Molecular Diagnostics and other markets.

Find out more about IsoPol™ DNA Polymerase.

ArcticZymes granted patent protection on its heat-labile Salt Active Nuclease in the USA

ArcticZymes AS has received a Notice of Allowance for the United States Patent Application No. US9422595 covering patentable subject matter of its heat-labile Salt Active Nuclease (HL-SAN) product.

With the approval of the new patent in the USA, ArcticZymes strengthens its rapidly growing intellectual property portfolio. The patent extends protection in the USA to the nucleic acid sequence of its HL-SAN product. The enzyme is an endonuclease capable of operating at high salt concentrations. This opens up a wider utility for use of such enzymes.

“The HL-SAN portfolio has typically been utilized by our customers in the preparation of nucleic acid-free products such as recombinant proteins and reagents. More recently, it has attracted growing interest from manufacturers of adeno-associated virus (AAV) for utility in gene therapy. The new patent greatly strengthens our commercial efforts.” says Managing Director, Jethro Holter at ArcticZymes AS.

ArcticZymes awarded funding from the Horizon 2020 programme

ArcticZymes has received EUR 460.000 over the next four years in a project funded by the European Framework Programme for Research and Innovation, Horizon 2020.

“We are excited to participate in the new granted “Virus-X” EU Consortium. It will allow ArcticZymes to expand its access to novel molecular enzymes via the bioprospecting of a wide diversity of viral genomes.”, says Jethro Holter, Managing Director, ArcticZymes AS.

The project “Viral Metagenomics for Innovation Value” (Virus-X), is a large collaboration project between a total of 15 partners from European research institutes, universities and industry with a total budget of nearly 8 M€, funded under Horizon 2020 – Research and Innovation Action (RIA). Viruses represent the largest reservoir of unknown genetic diversity on earth and the project aim to advance the understanding of viral ecosystems, diversity and virus-host interplay by DNA sequencing environmental libraries (metagenomes) from a number of different biotopes. The project is driven by the expected large innovation value and unique properties of viral gene products. Through an analysis and discovery pipeline, new enzymes for molecular biotechnology will be developed, and ArcticZymes is one of the industrial partners that will participate developing and bringing new viral enzymes to the market.

This is a milestone and great achievement of ArcticZymes. This acknowledges ArcticZymes experience and knowledge as a leading enzyme company within in the EU system, say Svein Lien, CEO, Biotec Pharmacon ASA.

GenomeWeb: “EU’s Horizon 2020 Awards ArcticZymes €460K Grant

What is Horizon 2020?